Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study

被引：165

作者：

Guignard, S. ^{[1
]}

Gossec, L. ^{[1
]}

Salliot, C. ^{[1
]}

Ruyssen-Witrand, A. ^{[1
]}

Luc, M. ^{[1
]}

Duclos, M. ^{[1
]}

Dougados, M. ^{[1
]}

机构：

[1] Univ Paris 05, Fac Med, APHP, Cochin Hosp,Rheumatol Dept B, F-72019 Paris, France

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷 / 12期

关键词：

D O I：

10.1136/ard.2006.052092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To evaluate the efficacy of anti-tumour necrosis factor (TNF) treatments (given for rheumatological manifestations) in reducing uveitis flares in patients with spondylarthropathy in daily practice. Methods: A retrospective observational study of all patients with spondylarthropathy with at least one uveitis flare treated with anti-TNF in one centre (December 1997 -December 2004). The number of uveitis flares per 100 patient-years was compared before and during anti-TNF treatment; each patient was his or her own control. The relative risk (RR) and the number needed to treat (NNT) were calculated. Results: 46 patients with spondylarthropathy treated with anti-TNF drugs had at least one uveitis flare (33 treated with anti-TNF antibodies, infliximab or adalimumab, and 13 with soluble TNF receptor, etanercept). The mean age at first symptoms was 26 years, 71% were men. Patients were followed for 15.2 years (mean) before anti-TNF versus 1.2 years during anti-TNF treatment. The number of uveitis flares per 100 patient-years before and during anti-TNF were, respectively: for all anti-TNF treatments, 51.8 v 21.4 (p = 0.03), RR = 2.4, NNT= 3 (95% confidence interval (CI = 2 to 5); for soluble TNF receptor 54.6 v 58.5 (p = 0.92), RR = 0.9; and for anti-TNF antibodies -50.6 v 6.8 (p = 0.001), RR = 7.4, NNT= 2 (95% CI = 2 to 5). Conclusion: Anti-TNF treatments were efficacious in decreasing the number of uveitis flares in patients with spondylarthropathy. Anti-TNF antibodies decreased the rate of uveitis flares, whereas soluble TNF receptor did not seem to decrease this rate. These results could have consequences for the choice of anti-TNF treatment in certain patients.

引用

页码：1631 / 1634

页数：4

共 15 条

[1]

AMOR B, 1990, REV RHUM, V57, P85

[2] Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept [J].

Braun, J ;

Baraliakos, X ;

Listing, J ;

Sieper, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2447-2451

[3] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[4] New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy [J].

Braun, J ;

de Keyser, F ;

Brandt, J ;

Mielants, H ;

Sieper, J ;

Veys, E .

CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (04) :245-249

[5]

Doubremelle M, 2002, GASTROEN CLIN BIOL, V26, P973

[6] Degree, duration, and causes of visual loss in uveitis [J].

Durrani, OM ;

Tehrani, NN ;

Marr, JE ;

Moradi, P ;

Stavrou, P ;

Murray, PI .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (09) :1159-1162

[7]

Falappone P C F, 2004, Reumatismo, V56, P185

[8]

Lacomba MS, 2001, OPHTHALMIC RES, V33, P251

[9] AN ASSESSMENT OF CLINICALLY USEFUL MEASURES OF THE CONSEQUENCES OF TREATMENT [J].

LAUPACIS, A ;

SACKETT, DL ;

ROBERTS, RS .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (26) :1728-1733

[10] Effect of infliximab on threatening panuveitis in Behcet's disease [J].

Muñoz-Fernández, S ;

Hidalgo, V ;

Fernández-Melón, J ;

Schlincker, A ;

Martín-Mola, E .

LANCET, 2001, 358 (9293) :1644-1644

← 1 2 →